Skip to main content
Aptose Biosciences Inc. logo

Aptose Biosciences Inc. — Investor Relations & Filings

Ticker · APS LEI · 5299003EUHV3CD08L949 TSX Professional, scientific and technical activities
Open in API
Filings indexed 267 across all filing types
Latest filing 2025-03-28 Regulatory Filings
Country CA Canada
Listing TSX APS

About Aptose Biosciences Inc.

https://www.aptose.com/

Aptose Biosciences Inc. is a clinical-stage biotechnology company dedicated to developing precision medicines and first-in-class targeted agents for life-threatening cancers, focusing primarily on hematologic malignancies. The company's strategy involves creating differentiated therapies designed for safe single-agent efficacy across multiple indications and enhanced combination potential without overlapping toxicities. Key investigational agents include Tuspetinib, a potent oral Myeloid Kinase Inhibitor (MKI) targeting SYK, FLT3, and JAK, currently in Phase 1/2 for relapsed or refractory Acute Myeloid Leukemia (AML). The pipeline also features Luxeptinib, a dual-acting Kinome Inhibitor. Luxeptinib acts as a Lymphoid Kinome Inhibitor (LKI) in Phase 1a/b trials for B-cell malignancies (CLL/NHL) by non-covalently inhibiting BTK, and as an MKI in Phase 1a/b trials for AML and high-risk Myelodysplastic Syndromes (MDS) by potently inhibiting FLT3.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is Form 52-109F1, a CEO/CFO certification under National Instrument 52-109 certifying the issuer’s annual filings (financial statements, MD&A, AIF). It is not the Annual Report itself, nor an earnings release or proxy statement, nor a notice of vote or dividend. It is a regulatory compliance certification rather than a substantive report. As there is no more specific category for this attestation, it falls into the fallback “Regulatory Filings” category (RNS).
2025-03-28 English
Report of Distributions outside Canada (Form 72-503F).pdf
Share Issue/Capital Change Classification · 1% confidence The document is a regulatory Form 72-503F “Report of Distributions Outside Canada,” detailing an exempt distribution (issuance) of common shares—including CUSIP, number of shares, prices and distribution date—by the issuer. It is not an earnings release, management discussion, or AGM material, but a formal notice of new share issuances as part of capital raising. Under the taxonomy, this fits “Share Issue/Capital Change” (SHA).
2025-03-27 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing compliance with Nasdaq’s minimum bid price requirement. It is not an annual or quarterly report, earnings release, proxy statement, or any other specific report type. It also is not a delisting notice but rather a regulatory compliance update. This fits the fallback category for miscellaneous regulatory announcements (Regulatory Filings).
2025-03-17 English
Other.pdf
Capital/Financing Update Classification · 1% confidence The document is a press release announcing a strategic partnership and long-term take-or-pay infrastructure agreement between Gibson Energy and Baytex, including a $50 million capital investment commitment and area dedication. There are no financial results or management changes, and it is not a formal filing of an annual or interim report. This falls under capital/financing updates covering strategic investment and infrastructure financing arrangements.
2025-03-11 English
Certificate and Articles of Amendment.pdf
Share Issue/Capital Change Classification · 1% confidence The document is a formal Certificate of Amendment under the Canada Business Corporations Act, specifically detailing a one-for-thirty share consolidation in the Articles of Amendment. This is a change to the company’s share capital structure rather than an earnings report, AGM materials, management change, or regulatory notice. Thus it falls under share capital changes (Share Issue/Capital Change).
2025-03-04 French
Material change report - English.pdf
Share Issue/Capital Change Classification · 1% confidence The document is a Form 51-102F3 Material Change Report filed under Canadian NI 51-102, detailing the company’s board approval and articles of amendment to implement a 1-for-30 reverse stock split (consolidation) of common shares. This is a corporate action directly altering the share capital structure, matching the “Share Issue/Capital Change” category (Code: SHA).
2025-02-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.